Singer Capital Markets appointed as Joint Broker to Oncimmune Holdings plc
Singer Capital Markets is pleased to announce our appointment as Joint Broker to Oncimmune Holdings plc with immediate effect.
Oncimmune is the 26th client Singer Capital Markets has been appointed to this year – more than any other broker in the UK small and mid-cap market.
About Oncimmune Holdings plc
Oncimmune was founded in 2002 and launched its platform diagnostic technology in 2009, followed by the launch of its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over 200,000 tests have been performed for patients worldwide. Oncimmune’s objective is to improve cancer survival and give people extra time through early detection and better selection for therapy.
Oncimmune’s immunodiagnostic test, EarlyCDT, is the world’s most thoroughly validated blood test. EarlyCDT Lung, for the detection of lung cancer, requires only a small volume of blood and has shown to detect lung cancer on average four years earlier compared to current standard clinical diagnosis. The EarlyCDT Lung blood test can also provide an effective assessment of cancer risk in indeterminate pulmonary nodules (IPNs).
The unique combination of Oncimmune’s core technology and understanding of the immune system, powers the ImmunoINSIGHTS service; a proprietary platform that enables life-science organisations to optimise drug development and delivery, leading to more effective, targeted as well as safer treatments for patients.
Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a partner representative office in Shanghai, China. Oncimmune joined the AIM Market of the London Stock Exchange in May 2016.
Market Cap: £89.8 million*
Website: Click here
*As at 12/08/2020